Patients with wet age-related macular degeneration (wet AMD) frequently discontinue anti-VEGF therapy within the first two years of treatment, leading to worse long-term visual outcomes. A retrospective analysis of over 200,000 eyes indicates that persistent treatment is essential for maintaining vision, yet significant attrition rates persist throughout the seven-year study period.
Trends in Anti-VEGF Treatment Persistence
Real-world data shows that adherence to anti-VEGF injection schedules often falters shortly after therapy begins. According to a study using the Vestrum Health database, 38.9% of eyes failed to continue treatment by the end of the first year, a figure that climbed to 52.6% by the end of the second year. Researchers defined nonpersistence as a treatment gap exceeding 180 days.
This decline in consistency is accompanied by a reduction in the frequency of care. The mean number of annual injections dropped from 8.4 in the first year to 6.2 by the seventh year. These findings suggest that the episodic nature of current treatment regimens may contribute to the observed "real-world" drop-off in patient engagement.
Factors Influencing Treatment Attrition
Clinical factors at the time of diagnosis significantly impact a patient’s likelihood of remaining on a treatment regimen. Analysis of the data revealed that patients presenting with baseline atrophy, fibrosis, or poor visual acuity were more likely to experience delays in initiating treatment.
Furthermore, the study identified a paradoxical relationship between injection frequency and persistence: patients who required more frequent interventions were statistically more likely to become nonpersistent. This suggests that the high burden of frequent office visits may be a primary driver of treatment fatigue.
Impact of Treatment Gaps on Vision
Consistent intravitreal therapy remains the clinical standard for preserving sight in wet AMD patients. While the study observed a gradual decline in visual acuity across all patient cohorts, those who maintained consistent, persistent treatment achieved superior long-term visual outcomes compared to those with significant treatment gaps.
Delayed initiation of treatment—defined as a wait time of 30 days or more—along with the presence of fibrosis or vitreous hemorrhage, was directly associated with diminished visual improvement.
Clinical Implications for Wet AMD Management
The data highlight a persistent gap between clinical trial efficacy and real-world outcomes. Dr. Andrew A. Moshfeghi, a retina specialist, notes that current findings underscore an urgent need for therapeutic approaches that provide longer-lasting effects.
Moving away from short, episodic treatment bursts toward therapies that offer continuous intraocular exposure could potentially mitigate the current rates of attrition. For clinicians, the findings emphasize the importance of patient education regarding the risks of treatment gaps and the necessity of maintaining a strict monitoring schedule, even when patients appear stable.
Key Findings at a Glance
- Early Attrition: Over half of patients (52.6%) discontinue treatment within the first two years.
- Injection Volume: Annual injection frequency decreases from an average of 8.4 in year one to 6.2 by year seven.
- Risk Factors: Baseline fibrosis, vitreous hemorrhage, and high treatment frequency are linked to poorer adherence and vision outcomes.
- Clinical Goal: Consistent, long-term anti-VEGF exposure is required to prevent progressive vision loss in wet AMD patients.
Related reading